日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

On-the-ground realities of health program delivery in addressing community needs: a community-based participatory research approach in the moose Cree First Nation

解决社区需求的卫生项目实施的实际情况:以驼鹿克里第一民族为例的社区参与式研究方法

F Balalio, Trisia Mae; A Robidoux, Michael

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

一项 III 期辅助治疗试验的最终结果比较了 6 个周期的 FEC-100 方案与 4 个周期的 AC 方案在可手术淋巴结阴性乳腺癌女性患者中的疗效:NSABP B-36 试验(NRG Oncology)

Geyer, Charles E Jr; Bandos, Hanna; Rastogi, Priya; Jacobs, Samuel A; Robidoux, André; Fehrenbacher, Louis; Ward, Patrick J; Polikoff, Jonathan; Brufsky, Adam M; Provencher, Louise; Paterson, Alexander H G; Hamm, John T; Carolla, Robert L; Baez-Diaz, Luis; Julian, Thomas B; Swain, Sandra M; Mamounas, Eleftherios P; Wolmark, Norman

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

更正:比较六个周期的 FEC-100 与四个周期的 AC 治疗可手术淋巴结阴性乳腺癌女性的 III 期辅助治疗试验的最终结果:NSABP B-36 试验(NRG Oncology)

Geyer, Charles E Jr; Bandos, Hanna; Rastogi, Priya; Jacobs, Samuel A; Robidoux, André; Fehrenbacher, Louis; Ward, Patrick J; Polikoff, Jonathan; Brufsky, Adam M; Provencher, Louise; Paterson, Alexander H G; Hamm, John T; Carolla, Robert L; Baez-Diaz, Luis; Julian, Thomas B; Swain, Sandra M; Mamounas, Eleftherios P; Wolmark, Norman

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

更正:NSABP FB-7:一项针对HER2阳性乳腺癌患者的II期随机新辅助治疗试验,采用紫杉醇联合曲妥珠单抗和/或奈拉替尼,随后进行化疗和术后曲妥珠单抗治疗。

Jacobs, Samuel A; Robidoux, André; Abraham, Jame; Pérez-Garcia, José Manuel; La Verde, Nicla; Orcutt, James M; Cazzaniga, Marina E; Piette, Fanny; Antolín, Silvia; Aguirre, Elena; Cortes, Javier; Llombart-Cussac, Antonio; Di Cosimo, Serena; Kim, Rim S; Feng, Huichen; Lipchik, Corey; Lucas, Peter C; Srinivasan, Ashok; Wang, Ying; Song, Nan; Gavin, Patrick G; Balousek, April D; Paik, Soonmyung; Allegra, Carmen J; Wolmark, Norman; Pogue-Geile, Katherine L

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

NSABP FB-7:一项针对HER2(+)乳腺癌患者的II期随机新辅助治疗试验,采用紫杉醇联合曲妥珠单抗和/或奈拉替尼,随后进行化疗和术后曲妥珠单抗治疗。

Jacobs, Samuel A; Robidoux, André; Abraham, Jame; Pérez-Garcia, José Manuel; La Verde, Nicla; Orcutt, James M; Cazzaniga, Marina E; Piette, Fanny; Antolín, Silvia; Aguirre, Elena; Cortes, Javier; Llombart-Cussac, Antonio; Di Cosimo, Serena; Kim, Rim S; Feng, Huichen; Lipchik, Corey; Lucas, Peter C; Srinivasan, Ashok; Wang, Ying; Song, Nan; Gavin, Patrick G; Balousek, April D; Paik, Soonmyung; Allegra, Carmen J; Wolmark, Norman; Pogue-Geile, Katherine L

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

一项比较三种化疗方案治疗可手术、淋巴结阳性乳腺癌女性患者的III期辅助治疗试验的最终结果:NSABP B-38试验

Swain, Sandra M; Tang, Gong; Geyer, Charles E Jr; Rastogi, Priya; Atkins, James N; Donnellan, Paul P; Fehrenbacher, Louis; Azar, Catherine A; Robidoux, André; Polikoff, Jonathan A; Brufsky, Adam M; Biggs, David D; Levine, Edward A; Zapas, John L; Provencher, Louise; Northfelt, Donald W; Paik, Soonmyung; Costantino, Joseph P; Mamounas, Eleftherios P; Wolmark, Norman